Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Welcome and Introduction to Vi3C

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Advertisement

Advertisement




Aug
07
Today In Oncology
mFOLFIRINOX and S-IROX vs Nab-Paclitaxel Plus Gemcitabine in Metastatic or Recurrent Pancreatic Cancer
Alpelisib Plus Olaparib vs Single-Agent Chemotherapy in Platinum-Resistant or -Refractory HGSOC Without BRCA Mutation
Potential New Second-Line Standard of Care Emerges in Small Cell Lung Cancer
Protease Activator Approved by the FDA for Diffuse Midline Glioma
RCC Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo